Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Interline Therapeutics Inc.
Headquarters: South San Francisco, CA, United States of America
Website: https://www.interlinetx.com/...
Year Founded: 2021
Status: Private
See Emerging Company Profile .
BioCentury | Oct 24, 2024
Management Tracks
Junaid Bajwa joins Flagship as senior partner, head of U.K.
Plus: Promotions at Citigroup and updates from FDA’s CDRH, LigaChem, Alphina, Kenai and Precision Medicine
BioCentury | Sep 5, 2024
Discovery & Translation
AI for target discovery: the start of a long road
Back to School 2024: Investments in AI in drug discovery pick up, as the picture starts to form of how target discovery may benefit
BioCentury | Jun 14, 2024
Finance
How Foresite is investing its $900M fund during the ‘first era’ of AI-driven R&D
Weeks after the firm co-led Xaira’s $1B round, Michael Rome looks ahead at ‘big themes’
BioCentury | May 7, 2024
Emerging Company Profile
Xaira’s $1B AI play: de novo antibodies now, causal biology to follow
Xaira will initially aim Baker tech at validated targets; functional genomics and patient data are its plan for “breaking the system” for target discovery
BioCentury | Apr 26, 2024
Finance
Venture report: Arch, Foresite $1B AI play Xaira starting with Baker lab’s de novo biologics
Plus rounds for Rubedo, Flindr, Endeavor, SynOx and more
BioCentury | Dec 1, 2022
Management Tracks
Lee to take the helm at SK Biopharmaceuticals
Plus: Amgen vet Tagari to join insitro as CSO, and updates from Haystack, Vaxxas, Akili and more
BioCentury | Aug 18, 2022
Management Tracks
PerkinElmer vet Mock becomes CFO at Moderna
Plus Huertas named CMO at Kriya, and updates from Opko Health and Foresite Labs
BioCentury | Mar 3, 2022
Finance
Foresite’s $173M fund to support incubator’s data-driven R&D projects
Offering flexibility to LP base, Foresite Capital raises complementary fund for company creation projects
BioCentury | Jun 5, 2021
Finance
How two new Foresite deals build on the firm’s investment in Relay, with computational tech and AI opening doors
Recent investments in Eikon, Interline continue push toward new data sets
BioCentury | May 13, 2021
Emerging Company Profile
Interline: correcting mutation-induced dysfunctional protein networks
Emerging Company Profile: Interline launches from Foresite Labs with platform to identify and fix altered protein networks in cancer, inflammation
Items per page:
1 - 10 of 10